Therapeutic Response Statement (Sensitivity) Deprecated

This therapeutic response statement Supports the relationship that CD117 + status confers therapeutic sensitivity to Imatinib in patients with Gastrointestinal Stromal Tumor.

The Republic of Ireland's Health Service Executive (HSE) has approved imatinib for reimbursement as a treatment option for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).

This statement is based on a regulatory approval from the Health Service Executive:

Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.

Citation

Imatinib Therapy - GIST, 2025, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6727/335_v4_Imatinib.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2016-06-20	Health Service Executive	Indication approved for reimbursement.